QUANTRO Therapeutics utilizes functional genetics and transcriptomics to create a novel cancer drug discovery pipeline that enhances the precision of cell-based compound screening. This approach addresses the need for more effective therapeutics in oncology by improving the identification of promising drug candidates.
Funding
$1.9M raised to dateRaised to date based on public sources. This may differ from the amount the company actually raised and is based only on what is publicly available on the internet.
Founders
Product
Problem
Traditional cell-based compound screening in cancer drug discovery often lacks the precision needed to identify truly effective therapeutics, leading to high failure rates in later stages of drug development. Current methods struggle to capture the complexity of cellular responses to drug candidates, resulting in a limited ability to predict clinical outcomes.
Solution
QUANTRO Therapeutics has developed a cancer drug discovery pipeline that leverages functional genetics and transcriptomics to enhance the precision of cell-based compound screening. Their approach, called Transcriptional Fingerprinting, combines innovative technologies to generate a novel platform that transforms the scope of cell-based compound screens. By exploiting functional-genetics and transcriptomics, QUANTRO aims to identify promising drug candidates with greater accuracy and predictability. This platform enables simultaneous multi-target screening, providing a more comprehensive understanding of drug mechanisms and their impact on cancer cells. The enhanced precision aims to improve the selection of drug candidates, increasing the likelihood of success in preclinical and clinical development.
Target Audience
The primary audience includes pharmaceutical companies, research institutions, and oncology drug developers seeking to improve the efficiency and success rate of their drug discovery programs.
Features
- Functional-genetics-based compound screening
- Transcriptomics-based compound screening
- Transcriptional Fingerprinting technology to enhance cell-based compound screens
- Simultaneous multi-target multiplex-screening
- Cell-based compound screens